Background Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients
with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years …

Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a
high prevalence in elderly patients and a propensity for progression to acute myeloid …

During the process of hematopoiesis, hematopoietic stem cells (HSCs) undergo hierarchical
differentiation and maturation to develop into mature effector cells through a tightly regulated …

Myelodysplastic syndromes (MDS) comprise hematological disorders that originate from the
neoplastic transformation of hematopoietic stem cells (HSCs). However, discrimination …

Myelodysplastic neoplasms (MDS) are characterized by clonal evolution starting from the
compartment of hematopoietic stem and progenitors cells (HSPCs), leading in some cases …

The analysis of hematopoietic stem and progenitor cell populations (HSPCs) is fundamental
in the understanding of normal hematopoiesis as well as in the management of malignant …

Objectives To examine flow cytometric (FCM) findings in clonal cytopenia of undetermined
significance (CCUS) in relation to variant allele fraction (VAF) and mutation risk. Methods …

Background Diagnosis of myelodysplastic syndromes (MDS) is often challenging and
requires integration of clinical, morphologic, cytogenetics and molecular information. Flow …

Острые лейкозы–химиотерапевтически излечимые заболевания, но даже при
достижении полной ремиссии у 85-90% больных острыми лейкозами риск развития …

Определение и мониторинг минимальной остаточной болезни (МОБ)-необходимые
компоненты программной терапии. Они имеют ключевое значение для выбора …